BPC-157 in 2026: Trials, Studies, and Lab Analysis
Last Updated: April 14, 2026
Research Use Only: BPC-157 is sold by Palmetto Peptides exclusively for laboratory and in vitro research purposes. It is not approved by the FDA for human or veterinary use. Nothing in this article constitutes medical advice.
BPC-157 in 2026: Trials, Studies, and Lab Analysis
The short answer: BPC-157 has one of the most robust preclinical research portfolios of any peptide studied in the last three decades — and one of the thinnest human trial records relative to that attention. As of 2026, no registered BPC-157 trials are actively recruiting, the FDA continues to classify it as a Category 2 bulk drug substance, and the total number of published human studies remains in the single digits. At the same time, peer-reviewed systematic reviews published in 2025 confirm that the preclinical evidence base is substantial, mechanistically coherent, and still expanding.
This annual research update covers where things actually stand: the trial history, what 2024 and 2025 studies added to the literature, how researchers evaluate lab-grade compound quality, and what the regulatory picture looks like heading into the second half of 2026. Researchers can review current compound availability on our BPC-157 research peptide page. For a comprehensive reference covering mechanisms, preclinical applications, and sourcing standards in one place, see the BPC-157 Complete Research Guide.
What Is BPC-157? A Quick Baseline
BPC-157 stands for Body Protection Compound-157. It is a synthetic pentadecapeptide — 15 amino acids — derived from a sequence found in human gastric juice. The compound was first isolated and studied by researchers at the University of Zagreb in Croatia beginning in the early 1990s, and the literature has since grown to include more than 100 preclinical studies.
The peptide is stable in gastric acid, unusual for most short-chain peptides. Its molecular weight is approximately 1,419.5 g/mol (CAS 137525-51-0). In laboratory settings it is typically supplied as a lyophilized (freeze-dried) powder and requires reconstitution before use — for reconstitution protocols see our BPC-157 reconstitution and storage lab protocol.
BPC-157 is not a hormone, not a steroid, and not a SARM. It is a research peptide studied for potential interactions with tissue repair signaling pathways, vascular biology, and gastrointestinal function in controlled preclinical environments.
The BPC-157 Clinical Trial Record: Where Things Stand in 2026
The Cancelled Phase I Trial (NCT02637284)
In 2015, PharmaCotherapia sponsored what was designed to be the first rigorous human pharmacokinetic study of BPC-157. The trial enrolled 42 healthy adult volunteers and aimed to establish safety and pharmacokinetic parameters for an oral formulation (marketed as Bepecin or PCO-02). In 2016, the submission of results was cancelled. No data was ever peer-reviewed or published publicly. To this day there is no peer-reviewed pharmacokinetic dataset for BPC-157 in humans. Dosing parameters cited online are extrapolated from animal studies.
Published Human Pilot Studies (2021–2025)
As of April 2026, three published human studies on BPC-157 exist. All were conducted by the same research group in Florida and none included a placebo control.
Intraarticular Injection for Knee Pain (Lee and Padgett, 2021). Retrospective review of 16 patients with chronic knee pain receiving a single intraarticular injection. Seven of 12 evaluable patients reported meaningful relief lasting more than six months. No adverse effects reported. This remains the most-cited human study in the BPC-157 literature.
Intravesicular Administration for Interstitial Cystitis (Lee, Walker, and Ayadi, 2024). Twelve patients received bladder instillations of BPC-157. All 12 reported significant improvement on the Global Response Assessment Questionnaire. Cystoscopic imaging showed resolution of inflammatory markers in at least one patient.
Intravenous Safety Pilot (Lee and Burgess, 2025). Two healthy adult volunteers received IV BPC-157 infusions at doses up to 20 mg. Both tolerated infusions with no adverse effects. Plasma levels returned to baseline within 24 hours — the only published IV safety data from a peer-reviewed source.
What Is Not in the Literature
The total human subject count across all published BPC-157 research is fewer than 30 people. There are no randomized controlled trials, no placebo groups, and no dose-response studies in humans. Rare adverse events would not be detectable in samples this small.
Key Peer-Reviewed Research in 2024 and 2025
Vasireddi et al., Orthopaedic Journal of Sports Medicine (2025)
The most comprehensive English-language systematic review of BPC-157 to date. The team screened 544 articles from database inception through June 2024 (PubMed, Cochrane, Embase). Of 36 included studies, 35 were preclinical animal models and 1 was a clinical study. The review found consistent preclinical evidence for improved musculoskeletal outcomes and confirmed BPC-157 is metabolized in the liver (half-life < 30 min), cleared via the kidneys, and detectable in urine by MS for up to four days. No toxic or lethal dose was established in preclinical toxicology. The authors concluded that clinical safety in humans remains unknown. See our deep dive on BPC-157 safety profile and preclinical research findings.
McGuire et al., Current Reviews in Musculoskeletal Medicine (2025)
This scoping review reinforced BPC-157's mechanisms acting through VEGFR2 upregulation and the Akt-eNOS axis, while also engaging ERK1/2, FAK-paxillin, and cytoprotective pathways including HO-1 and heat shock proteins.
Józwiak et al., Pharmaceuticals (2025)
Synthesized the full breadth of BPC-157 biological activity and patent history, raising theoretical concerns about long-term angiogenesis pathway stimulation. A published rebuttal from the Sikiric group (Pharmaceuticals, September 2025) followed — reflecting a healthy emerging scientific debate that remains confined to preclinical models.
How BPC-157 Works: The Core Signaling Pathways
For a full mechanistic breakdown, see our dedicated article on BPC-157 mechanism of action at the cellular level.
Angiogenesis via VEGFR2. BPC-157 consistently upregulates VEGFR2, which activates Akt → eNOS → nitric oxide production. This drives new vessel formation and improves tissue perfusion at injury sites.
Nitric Oxide Modulation. BPC-157 acts as a bidirectional modulator: increasing NO bioavailability in ischemic states and reducing pathological overproduction in endotoxemia models. This relationship involves all three NOS isoforms.
ERK1/2 and Cell Growth Signaling. BPC-157 upregulates ERK1/2 phosphorylation, promoting cell proliferation and migration. ERK inhibition blocks BPC-157-driven endothelial cell tube formation in cell studies.
Anti-Inflammatory Cytokine Modulation. Preclinical models consistently show reductions in TNF-alpha, IL-6, and MPO — an anti-inflammatory profile that appears context-dependent rather than broadly immunosuppressive.
BPC-157 Research Landscape: Evidence Summary
| Research Area | Preclinical Evidence | Human Clinical Data |
|---|---|---|
| Musculoskeletal repair | Extensive (30+ animal studies) | 1 retrospective pilot (n=16) |
| Gastrointestinal protection | Substantial | Phase II UC data (Croatia, early 2000s) |
| Angiogenesis / vascular biology | Well-characterized mechanistically | None |
| Neurological / CNS models | Preliminary, growing | None |
| Urological | Indirect (anti-inflammatory models) | 1 pilot (n=12, 2024) |
| IV safety / pharmacokinetics | Animal PK data | 1 pilot (n=2, 2025) |
| Long-term safety | No adverse findings in acute models | No data |
For a deeper look at the full preclinical application spectrum, see our article on BPC-157 in vitro and in vivo research applications.
Lab Analysis: What Research-Grade BPC-157 Quality Testing Looks Like
Why Analytical Standards Matter
BPC-157 is synthesized via Solid-Phase Peptide Synthesis (SPPS). If not controlled precisely, this multi-step process can produce truncated or incomplete sequences alongside the target compound. Independent third-party analytical data from 469 samples across 69 vendors found purity ranging from 96.25% to 99.95% — with quantity deviations up to ±80% at the extremes. For a complete sourcing guide, see our article on sourcing research-grade BPC-157: quality, purity & COA standards.
HPLC: The Purity Standard
HPLC separates the compound through a chromatography column, producing a chromatogram with peaks for each component. A properly synthesized BPC-157 sample should show one dominant peak. Research-grade material is generally considered reliable at ≥99% purity.
Mass Spectrometry: Identity Confirmation
HPLC confirms purity but not identity. MS confirms the molecular weight: BPC-157 (CAS 137525-51-0) should measure approximately 1,419.5 g/mol. HPLC ≥99% + MS identity match = strong analytical confirmation.
Endotoxin Testing
Endotoxins (LPS from bacterial membranes) can produce profound inflammatory responses in cell-based assays, confounding results. LAL testing or equivalent endotoxin assays are standard in a complete peptide COA.
What a Complete COA Should Include
Batch number, manufacture date, HPLC purity with chromatogram, MS molecular weight confirmation, retention time identity, UV spectral comparison, endotoxin test results, sample mass, and the name of the independent third-party laboratory.
Regulatory and Legal Status in 2026
FDA Category 2 Designation (2023). Compounding pharmacies cannot legally prepare BPC-157. This does not make it illegal to possess or supply as a research chemical. For the full regulatory picture, see our article on BPC-157 regulatory status in 2026.
Research Chemical Status. BPC-157 is not DEA-scheduled. Legally sold by licensed research suppliers for in vitro and laboratory use only. Not approved as a drug or dietary supplement.
WADA Prohibited List. Detectable in urine by MS for up to four days. Athletes subject to anti-doping controls should be aware.
BPC-157 vs. Related Research Peptides
For a detailed comparison, see BPC-157 vs TB-500: Comparing Two Key Research Peptides.
| Peptide | Primary Preclinical Research Focus | FDA Status |
|---|---|---|
| BPC-157 | Musculoskeletal repair, GI protection, angiogenesis | Category 2 |
| TB-500 | Tissue repair, actin regulation, anti-inflammation | No approved use |
| GHK-Cu | Skin regeneration, wound healing, antioxidant activity | No approved use |
| IGF-1 LR3 | Muscle cell signaling, proliferation models | No approved use |
For the Wolverine Stack combining BPC-157 and TB-500, see the BPC-157 + TB-500 Wolverine Stack complete guide. For compliance context, see our article on the legal status of BPC-157 and TB-500 for laboratory use. Lab supplies including Bacteriostatic Water are also available for reconstitution needs.
Return to the BPC-157 Complete Research Guide for the full reference resource.
2026 Summary: What We Know and What Remains Open
What the literature supports: The preclinical evidence base is large, growing, and mechanistically coherent. Multiple independent research groups have replicated core findings. Recent 2025 systematic reviews have synthesized this literature effectively.
What remains unresolved: Human clinical data is limited to three small pilot studies totaling fewer than 30 subjects. No RCTs. No placebo comparisons. No established human pharmacokinetics from peer-reviewed sources. No long-term human safety data. The 2016 Phase I cancellation left a fundamental data gap still unfilled.
Frequently Asked Questions
Are there active BPC-157 clinical trials in 2026? No registered trials are actively recruiting on ClinicalTrials.gov as of early 2026. The most recent human data is the 2025 IV safety pilot (n=2) and 2024 interstitial cystitis pilot (n=12). BPC-157 is available for laboratory and in vitro research use only.
What is BPC-157's FDA status in 2026? Category 2 bulk drug substance — compounding pharmacies cannot legally prepare it. Not FDA-approved as a drug or supplement. Legally available through licensed research suppliers for in vitro and lab use only.
What lab testing verifies BPC-157 purity? HPLC (purity percentage) + Mass Spectrometry (molecular identity) + endotoxin screening. A complete COA from an independent third-party lab should document all three.
How does BPC-157 work at a molecular level? Key mechanisms in preclinical research: VEGFR2 upregulation (angiogenesis), Akt-eNOS axis (nitric oxide), ERK1/2 (cell growth and migration), and downregulation of TNF-alpha and IL-6. All findings are from preclinical animal and in vitro studies.
Is BPC-157 the same as TB-500? No. BPC-157 is a 15-amino acid gastric juice sequence. TB-500 is a Thymosin Beta-4 fragment. Different structures, different mechanisms — not interchangeable.
Peer-Reviewed Citations
- Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. Orthopaedic Journal of Sports Medicine. 2025. PMC12313605.
- McGuire F, et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Current Reviews in Musculoskeletal Medicine. 2025;18(12):611–619. PMC12446177.
- Józwiak P, et al. Multifunctionality and possible medical application of the BPC 157 peptide. Pharmaceuticals. 2025;18(2):185.
- Sikiric P, et al. BPC 157 therapy: targeting angiogenesis and nitric oxide. Pharmaceuticals. 2025;18(10):1450. PMC12567428.
- Lee E, Burgess K. Safety of IV infusion of BPC157 in humans: a pilot study. Alternative Therapies in Health and Medicine. 2025;31(5):20–24.
- Lee E, Walker C, Ayadi B. Effect of BPC-157 on interstitial cystitis: a pilot study. Alternative Therapies in Health and Medicine. 2024;30(10):12–17.
- Lee E, Padgett B. Intra-articular injection of BPC 157 for knee pain. Alternative Therapies in Health and Medicine. 2021;27(4):8–13.
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2. Journal of Molecular Medicine. 2017;95:323–333.
- Hsieh MJ, et al. Modulatory effects of BPC 157 on vasomotor tone and Src-Caveolin-1-eNOS pathway. Scientific Reports. 2020;10:17078.
- Sikiric P, et al. The stable gastric pentadecapeptide BPC 157 pleiotropic beneficial activity. PMC. 2024. PMC11053547.
Updated annually to reflect new peer-reviewed publications and regulatory developments. All information is for educational and research reference only. BPC-157 is sold exclusively for in vitro laboratory research use. Not intended for human or veterinary use. Not medical advice.
Author: Palmetto Peptides Research Team